Clinical Trial

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

Study acronym: ET-902-AID01
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-30.
Trial Details
NCT Number NCT07212322
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome, Antiphospholipid Syndrome, Immune Thrombocytopenia, Systemic Sclerosis
Enrollment 24 participants
Start Date 2026-01-30
Primary Completion 2027-05-20 (estimated)
Study Completion 2027-07-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-19